Article
Direct evidence for the absence of intercellular trafficking of VP22 fused to GFP or to the herpes simplex virus thymidine kinase.
Gene therapy - 1 Jan 2005
Roy V, Qiao J, de Campos-Lima P, Caruso M
Abstract excerpt
The treatment of solid tumors by retroviral delivery of the herpes simplex virus thymidine kinase (TK) followed by ganciclovir (GCV) treatment has so far shown only limited success in patients. One major drawback in this approach is the lack of efficient in vivo gene delivery to cancer cells. Although, the transduction of every single tumor cell is not a requirement since the bystander effect (BE) mediated by gap...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
